Figure 1. Inhibition of osteosarcoma cancer cell proliferation by genetically engineered miR-34a prodrug.

(A) Dose-response curves for the effects of tRNA/miR-34a versus control tRNA/MSA on 143B and MG-63 cell viability. (B) The estimated pharmacodynamic parameters. Cell viability was determined using MTT assay at 72 h post-treatment, which was suppressed to a significantly (P < 0.001, two-way ANOVA) greater degree by tRNA/mir-34a than tRNA/MSA. This is also indicated by a lower EC50 and Bottom value (P < 0.05, one-way ANOVA). Values are mean ± SD of triplicate treatments.